Mentioned in ?
References in periodicals archive ?
There are no large outcome studies, but it seems to be most useful in patients with unexplained or premature arteriosclerotic cardiovascular disease in the face of otherwise normal lipids," Dr.
Tokyo, Japan, Oct 28, 2005 - (JCNN) - Daiichi Sankyo announced on October 26 that its subsidiary Sankyo has decided to cease its ongoing clinical studies of pactimibe (CS-505), an investigational drug for the treatment of arteriosclerotic cardiovascular disease (ASCVD).
Patients with chronic renal disease have high morbidity and mortality resulting from arteriosclerotic cardiovascular disease (CVD).